Bill to Expand Epinephrine Access Filed in Senate

Sens. Gary Peters of Michigan and Mike Braun of Indiana filed a bipartisan bill that would expand access to epinephrine.

Epinephrine is a lifesaving medicine used to treat anaphylaxis, a severe allergic reaction.

The bill, known as Dillon’s Law, offers incentives to states if they allow trained people to carry and give epinephrine in an emergency. It also requires that these people be protected from civil liability for giving someone epinephrine.

Dillon's Law is named after Dillon Mueller, a teenage boy whose life was cut short due to a severe allergic reaction to a bee sting. Dillon had never had such a reaction before and did not have a prescription for epinephrine. This bill honors his memory and aims to prevent similar tragedies.

Click here to use our online tool to let your legislators know you support Dillon’s Law.

A National Conversation About the High Cost of Asthma Inhalers

Your Support Means We Can Advocate

Recent events, like the discontinuation of Flovent brand inhalers and a Senate committee investigation into inhaler pricing, are shining a light on the burden of asthma. The asthma community needs access to critical, lifesaving medicines. Now is the time to address the barriers that prevent the effective treatment of asthma.
 
AAFA is a trusted source of information on what matters most to people with asthma. We share our asthma research and patient insights on disease burden to advocate for better health care for our community.
 
With your support, we can break down walls that are blocking access to affordable asthma medicines. You can help by making a special contribution to AAFA's vital advocacy efforts today.

DONATE TODAY

Brand Name vs. Generic Medicines: What's the Difference?

RESEARCH NEWS

Here's the latest asthma and allergy research news:

Anaphylaxis and Atopic Dermatitis

• New Guidelines Released for Health Care Providers Treating Anaphylaxis and Atopic Dermatitis
• Northwestern Researchers Are Developing a Therapy to Prevent Allergic Reactions
• DUPIXENT® (Dupilumab) U.S. Label Updated with Data Further Supporting Use in Atopic Dermatitis with Moderate-To-Severe Hand and Foot Involvement

• Disparities in Asthma Attacks, ED Visits Narrow for Black Patients During Pandemic

• FDA Grants Priority Review to XOLAIR® (Omalizumab) for Children and Adults with Food Allergies Based on Positive National Institutes of Health Phase III Study Results

• EDS-FLU Reduces Symptoms of Chronic Rhinosinusitis Regardless of Nasal Polyps

CLINICAL TRIALS

Are You Currently Taking Oral Corticosteroids (OCS) for Your Asthma?

Would you like to contribute to important new research? SUNRISE is a clinical study investigating whether a new biologic treatment called tezepelumab may help to reduce or remove the need for OCS in adults with severe asthma. The study is looking for people who:

• Are between 18 and 80 years of age
• Have had an asthma diagnosis for at least 1 year
• Have been taking OCS for asthma for at least 6 months
• Have been using inhaled corticosteroids for at least a year, and a long-acting beta 2-agonist (LABA) for at least 3 months
• Have not been receiving any biologic treatment for asthma for at least 4 months

Sponsored by AstraZeneca
 

LEARN MORE

INTERVIEWS AND FOCUS GROUPS

Research Opportunity: Caregivers for Children with Asthma

A Doctor of Nursing Practice (DNP) student at Regis College is recruiting for a project about caregivers and how well they cope with mental health symptoms while caring for a child with asthma. Your participation may help other caregivers like you. To be eligible, you must:

• Have a child of any age with a diagnosis of asthma who requires albuterol or steroid inhalers for management
• Be 18 years of age or older

You will be asked to complete a one-time, 15-minute survey about yourself and participate in a one-hour interview over Zoom in a group setting. You will be given a $10 Amazon e-gift card at the completion of this project.

If you have any questions, please contact Timarra Warren by email or phone at: twar860@regiscollege.edu or 470-541-8440.

LEARN MORE 

Did You Miss Our Last Issue?

Check out our previous issue for information on the Flovent discontinuation, biologics for asthma, and more …

                                   READ THE LATEST ISSUE

Thank you for your continued support.
Visit aafa.org and kidswithfoodallergies.org